ONCONASE Plus Doxorubicin Versus Doxorubicin Alone For Patients With Malignant Pleural or Peritoneal Mesothelioma Who Have Had No More Than One Prior Chemotherapy Regimen - Related Studies

ONCONASE Plus Doxorubicin Versus Doxorubicin Alone For Patients With Malignant Pleural or Peritoneal Mesothelioma Who Have Had No More Than One Prior Chemotherapy Regimen

This study is ongoing, but not recruiting participants.

Study NCT00003034. Last updated on July 23, 2008. Information provided by National Cancer Institute (NCI)

Find Related Studies by Searching for the Conditions, Interventions, and Sponsors found in this study:


1	Conditions listed in this trial
		Malignant Mesothelioma

2	Additional conditions recognized in this trial
		Mesothelioma

3	More general conditions related to this trial
		Adenoma
		Neoplasms
		Neoplasms by Histologic Type
		Neoplasms, Glandular and Epithelial
		Neoplasms, Mesothelial

4	Interventions listed in this trial
		doxorubicin hydrochloride
		ranpirnase

5	Additional drug interventions recognized in this trial
		Doxorubicin

6	More general drug interventions related to this trial
		Antibiotics, Antineoplastic
		Antineoplastic Agents
		Enzyme Inhibitors
		Molecular Mechanisms of Pharmacological Action
		Pharmacologic Actions
		Protein Synthesis Inhibitors
		Therapeutic Uses

7	Sponsors listed in this trial
		Alfacell